# Modulari-T

Source: https://onco.cc/companies/modulari-t/  
OnCo record `modulari-t` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Modulari-T designs synthetic genes that let engineered immune cells sense their surroundings and change behaviour, so cell therapies can find and kill cancer more reliably.

## Summary

Modulari-T, based in Montreal with a San Francisco presence, has designed a family of synthetic genetic modules that reprogramme cells to sense environmental cues and respond, applied first to engineering T cells and other immune cells that recognise and kill tumour cells more efficiently, with a stated ambition to become a platform for all cell engineering including regenerative medicine. The company is preclinical; no sourced financing rounds are recorded.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- Tags: yc
- HQ: Montreal
- Type: cell-therapy
- Website: https://modularit.bio

## Sources

- Y Combinator profile: https://www.ycombinator.com/companies/modulari-t
- Official website: https://modularit.bio

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/)
- technologies: [Armoured, logic-gated & next-gen CARs](https://onco.cc/technologies/armored-car/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- companies: [Y Combinator](https://onco.cc/companies/y-combinator/)

---
JSON: https://onco.cc/api/v1/entities/modulari-t.json